Clinical Trial Update: A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 study of selpercatinib in RET fusion-positive non-small cell lung cancer; results have been posted and the trial status is a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Selpercatinib (selpercatinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-20